FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      
           
This page is updated frequently with new Expression Vector-related patent applications. Subscribe to the Expression Vector RSS feed to automatically get the update: related Expression RSS feeds. RSS updates for this page: Expression Vector RSS RSS


Date/App# patent app List of recent Expression Vector-related patents
05/21/15
20150143585
 Biomass production increasing gene and transgenic plant using same patent thumbnailnew patent Biomass production increasing gene and transgenic plant using same
The present disclosure relates to, inter alia, a gene for increasing biomass production isolated from arabidopsis thaliana, and a method for producing a transgenic plant by using the same. More specifically, the present disclosure provides, inter alia, a composition for increasing production of plant biomass, a recombinant expression vector and a transgenic plant, comprising a base sequence encoding for the amino acid sequence of sequence number 2.
Postech Academy-industry Foundation
05/21/15
20150143556
 Mutant alpha-synuclein, and methods using same patent thumbnailnew patent Mutant alpha-synuclein, and methods using same
The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (a56), at the alanine at position 76 (a76), at the methionine at position 127 (m127) and/or at the valine at position 118 (v118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
05/21/15
20150141347
 Murine anti-ny-eso-1 t cell receptors patent thumbnailnew patent Murine anti-ny-eso-1 t cell receptors
The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serv.
05/21/15
20150140607
 Cho expression system patent thumbnailnew patent Cho expression system
The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a cho cell line.
Sanofi
05/21/15
20150140591
 Cell engineering using rnas patent thumbnailnew patent Cell engineering using rnas
The invention concerns the field of cell culture technology. It concerns rna having a specific sequence, expression vectors encoding said rna, production host cell lines comprising said rna, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said rnas, such as small non-coding rnas, preferably micrornas (mirnas).
Boehringer Ingelheim International Gmbh
05/14/15
20150135360
 Stress tolerance in plants patent thumbnailStress tolerance in plants
Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress).
05/14/15
20150133379
 Cosmetic composition for improving skin conditions comprising fusion protein patent thumbnailCosmetic composition for improving skin conditions comprising fusion protein
The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein.
05/14/15
20150132823
 Alpha-amylase variants patent thumbnailAlpha-amylase variants
The invention relates to a variant of a parent termamyl-like alpha-amylase, comprising mutations in two, three, four, five or six regions/positions. The variants have increased stability at high temperatures (relative to the parent).
05/14/15
20150132770
 Pregnancy-associated plasma protein-a2 (papp-a2) polynucleotides patent thumbnailPregnancy-associated plasma protein-a2 (papp-a2) polynucleotides
The present invention provides pregnancy associated plasma protein a2 (papp-a2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode papp-a2, expression vectors for the production of purified papp-a2, antibodies capable of binding specifically to papp-a2, hybridization probes or oligonucleotides for the detection of papp-a2-encoding nucleotide sequences, genetically engineered host cells for the expression of papp-a2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of papp-a2, are also described..
05/07/15
20150126456
 Method and pharmaceutical composition for use in the treatment of cancer patent thumbnailMethod and pharmaceutical composition for use in the treatment of cancer
The present invention relates to a soluble peptide comprising the amino acids sequence: krfyvvmwkk (seq id no: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier..
Assistance Publique-hopitaux De Paris
05/07/15
20150126452

Protein assembler


The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc.
Albert-luding-universitÄt Freiburg
05/07/15
20150125951

Mutant alpha-synuclein, and methods using same


The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (a56), at the alanine at position 76 (a76), at the methionine at position 127 (m127) and/or at the valine at position 118 (v118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
04/30/15
20150119332

Isoform-selective inhibitors and activators of pde3 cyclic nucleotide phosphodiesterases


The present invention concerns methods and compositions related to type 3 phosphodiesterases (pde3). Certain embodiments concern isolated peptides corresponding to various pde3a isoforms and/or site-specific mutants of pde3a isoforms, along with expression vectors encoding such isoforms or mutants.
The United States Government, As Represented By The Department Of Veterans Affairs
04/30/15
20150118754

Stable expression system for eukaryotic cells


The present invention related to a polynucleotide sequence and an expression vector comprising at least one gene encoding a stress resistance protein, at least one gene encoding a selection marker, at least one gene encoding an expression protein, at least one matrix attachment region and a transcription terminator, all of which are operably connected to each other. The present invention further relates to a host cell comprising the expression vector.
Biogenomics Limited
04/30/15
20150118744

Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector


An oligonucleotide that inhibits the binding of a serine/arginine-rich protein 30c (srp30c) to a pre-mrna of a glucocorticoid receptor gene in vivo.. .
National University Corporation Tokyo University Of Agriculture And Technology
04/23/15
20150110744

Peptide agents for cancer therapy


There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence rxkxkxxxxr wherein k and r are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence rskaknplyr (seq id. No.
Inter-k Pty Limited
04/16/15
20150106971

Threonine synthase from nicotiana tabacum and methods and uses thereof


There is disclosed a mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a threonine synthase and having at least 90% sequence identity to seq id no:1, seq id no:2 or seq id no:3 or at least 87% sequence identity to seq id no:4, or seq id no:5; (ii) a polypeptide encoded by any one of said polynucleotides set forth in (i); or (iii) a polypeptide having at least 95% sequence identity to seq id no:6, seq id no:7 or seq id no:8; or (iv) a construct, vector or expression vector comprising the polynucleotide as set forth in (i).. .
Philip Morris Products S.a.
04/16/15
20150104870

Neuronal differentiation promoter


The present invention provides an agent for promoting neuronal differentiation of neural stem cells, which contains a p38 inhibitor. In addition, the present invention provides a method of promoting neuronal differentiation of neural stem cells, which includes cultivating neural stem cells in the presence of a p38 inhibitor.
Keio University
04/16/15
20150104866

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.
04/16/15
20150104832

Method for modulating gene expression by modifying the cpg content


The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of cpg dinucleotides. The invention also relates to modified nucleic acids and expression vectors..
Geneart Ag
04/16/15
20150104433

Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains


The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (ltr) of proviral dna of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
04/09/15
20150099707

Modified pseudomonas exotoxin a


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
Hoffmann-la Roche Inc.
04/09/15
20150098925

Compositions and methods for treating cardiovascular diseases using disease-specific promoter


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microrna, sirna or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body.
Kiromic, Llc
04/02/15
20150093392

Antibodies


The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to cdh17 with high affinity. Nucleic acid molecules encoding cdh17 antibodies, expression vectors, host cells and methods for expressing cdh17 antibodies are also provided.
Oxford Bio Therapeutics Ltd
03/26/15
20150087054

Importation of mitochodrial protein by an enhanced allotopic approach


An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)
03/26/15
20150087053

Compositions and methods for increasing the expression and signalling of proteins on cell surfaces


The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces.
The Johns Hopkins University
03/26/15
20150087047

Process for production of recombinant proteins as a soluble form


A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein.
Jnc Corporation
03/26/15
20150086588

Parainfluenza virus 5 based vaccines


The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (piv5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (hn) gene and the large rna polymerase protein (l) gene of the piv5 genome.
University Of Georgia Research Foundation, Inc.
03/19/15
20150079070

Hyperglycosylated binding polypeptides


Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a ch1 domain (e.g., a human igg1 ch1 domain), wherein the ch1 domain has an engineered n-linked glycosylation site at amino acid position 114, according to kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation
03/12/15
20150072898

Broad host range expression vector for diverse prokaryotes


The invention relates to a synthetic nucleic acid molecule for expressing at least one nucleotide sequence of interest in at least one prokaryotic host cell, comprising, amongst others, at least one replication module comprising at least one replication cassette for promoting replication of the nucleic acid molecule in gram-negative organisms and at least one replication cassette for promoting replication of the nucleic acid molecule in gram-positive organisms, and at least one expression module for promoting expression of the nucleotide sequence of interest in the host cell, wherein each module is flanked at both ends by at least one unique restriction site. The invention further concerns a method for producing a shuttle vector comprising several modules, wherein said shuttle vector is designed by selecting each of said modules such that the vector is optimized for its intended use..
Westfaelische Wilhelms-universitaet Muenster
03/12/15
20150072417

Method of nuclear reprogramming


A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an oct family gene, a klf family gene, a sox family gene, a myc family gene, a lin family gene, and nanog gene.
Kyoto University
03/12/15
20150072368

Transcription units and the use thereof in expression vectors


Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium..
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
03/05/15
20150065376

Expression constructs encoding g protein coupled receptors and methods of use thereof


Expression vectors comprising a first nucleic acid sequence encoding a g protein coupled receptor (gpcr), wherein the gpcr encoded thereby is expressed as a fusion protein with a first detectable marker/signal, and a second nucleic acid sequence encoding a second polypeptide that is or comprises a second detectable marker/signal, wherein the second polypeptide is expressed as a fusion protein with a membrane localizing sequence are encompassed herein. The first nucleic acid sequence encoding the gpcr and the second nucleic acid sequence encoding the second polypeptide are under the transcriptional control of the same promoter and are operably linked via, for example, an internal ribosomal entry site (ires).
03/05/15
20150064209

Methods for generating immunity to antigen


Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen.
Microvax, Llc
02/26/15
20150059015

Fungal resistant plants expressing acd


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an acd protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh
02/26/15
20150056210

Anti-adamts-5 antibody, derivatives and uses thereof


The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the spacer domain of adamts-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.. .
Rottapharm Biotech S.r.l.
02/26/15
20150056168

Bacterial expression system


The present invention provides a bacterial expression system for expressing a nucleic acid comprising: (a) dna encoding a group 5 rna polymerase sigma factor; and (b) an expression cassette comprising a promoter recognised by the group 5 rna polymerase sigma factor operably linked to a heterologous nucleic acid; wherein (a) and (b) are located on the same expression vector, separate expression vectors or are integrated into the bacterial host genome.. .
The University Of Nottingham
02/19/15
20150052629

Fungal resistant plants expressing ocp3


The present invention relates to a method of increasing resistance against fungal pathogens of the family phacosporaceae in plants and/or plant cells. This is achieved by increasing the expression of an ocp3 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh
02/19/15
20150051267

Bicistronic gene transfer tools for delivery of mirnas and protein coding sequences


Compositions and methods relating to microrna (mirna) technology are disclosed. In particular, microrna (mirna) expression vectors and methods for the treatment of sensory disorders, e.g., for the treatment of hearing loss, are described..
Purdue Research Foundation
02/19/15
20150050270

Antibodies to bradykinin b1 receptor ligands


The invention provides antibodies that specifically bind to kallidin or des-arg10-kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-kallidin or des-arg10-kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof.
Sanofi
02/12/15
20150044753

Expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a preparing a target protein employing the same


The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (gs), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified gs having an increased sensitivity to a glutamine synthetase (gs) inhibitor, a polynucleotide encoding the modified gs, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant..
Hanwha Chemical Corporation
02/12/15
20150044712

Method and kit for analyzing protein-protein interaction using nanocluster formation


For efficient analysis of a protein-protein interaction, the present disclosure provides a kit for analyzing a protein-protein interaction, the kit including: a 1st expression vector including a 1st polynucleotide and a multi-cloning site, wherein, the 1st polynucleotide is operably linked to a promoter and encodes a 1st fusion protein having a 1st fluorescence protein and a 1st self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a bait protein may be operably linked to the polynucleotide encoding the 1st fusion protein; and a 2nd expression vector including a 2nd polynucleotide and a multi-cloning site, wherein, the 2nd polynucleotide is operably linked to a promoter and encodes a 2nd fusion protein having a 2nd fluorescence protein and a 2nd self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a prey protein may be operably linked to the polynucleotide encoding the 2nd fusion protein.. .
Korea Advanced Institute Of Science And Technology
02/05/15
20150038675

Peptide having affinity for silicon nitride (si3n4), and use thereof


The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride. The invention involves a peptide having an affinity for silicon nitride, the peptide comprising (1-1) a peptide having the amino acid sequence of one of seq id nos: 1, 2 and 23 to 27, (1-2) a peptide that has an affinity for silicon nitride and comprises an amino acid sequence obtained by deleting, adding, and/or substituting one or more amino acids in one of the amino acid sequences indicated in (1-1), or a fragment of one of the peptides..
National University Corporation Kyoto Institute Of Technology
02/05/15
20150038408

Polypeptides for treating and/or limiting influenza infection


The present invention provides polypeptides that recognize and are strong binders to influenza a hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention.
University Of Washington Through Its Center For Commercialization
02/05/15
20150037880

Dna encoding canine monomeric crp and expression vector containing the dna


Pentameric crp is produced at a high efficiency by transferring dna, which encodes monomeric crp, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric crp that is produced by the transgenic silkworm constructed above.. .
National Institute Of Agrobiological Sciences
02/05/15
20150037371

Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens


The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite).
The Administrators Of The Tulane Educational Fund
01/29/15
20150031624

Anti-mesothelin chimeric antigen receptors


The invention provides a chimeric antigen receptor (car) (a) an antigen binding domain of hn1 or ss, a transmembrane domain, and an intracellular t cell signaling domain, or (b) an antigen binding domain of ss1, a transmembrane domain, an intracellular t cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (gm-csf) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
Office Of Health And Human Services, Nih
01/29/15
20150030605

Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof


The invention encompasses polypeptides, polynucleotides, and antibodies, for artemin and related ligands, including persephin (pspn). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies.
Auckland Uniservices Limited
01/29/15
20150030601

E1 enzyme mutants and uses thereof


The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted.
Millennium Pharmaceuticals, Inc.
01/29/15
20150030597

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer


The invention provides chimeric antigen receptors (cars) comprising an antigen binding domain of a kdr-1121 or dc101 antibody, an extracellular hinge domain, a t cell receptor transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
01/22/15
20150024498

Cldn5 mini-promoters


Isolated polynucleotides comprising a cldn5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
01/22/15
20150024036

Targeting rnas to microvesicles


Disclosed herein is an isolated nucleic acid molecule comprising a first nucleic acid sequence 5′-accctgccgcctggactccgcctgt-3′ (seq id no: 22), or a functional variant thereof, operably linked to a second, heterologous nucleic acid sequence. The isolated nucleic acid molecule can be dna (in an expression vector) and rna (mrna, shrna, orncrna).
The General Hospital Corporation
01/22/15
20150023988

Potent and selective inhibitors of nav1.7


Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of nav1.7.
Amgen Inc.
01/15/15
20150017692

Beta-glucosidase


The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017691

ß-glucosidase


The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017690

Beta-glucosidase


The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 91% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co., Ltd.
01/15/15
20150017689

ß-glucosidase


The present invention relates to a polypeptide which has β-glucosidase activity, and which includes an amino acid sequence represented by seq id no: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by seq id no: 1, or a polypeptide including an amino acid sequence having 90% or greater sequence identity with the amino acid sequence represented by seq id no: 1. According to the present invention, a novel β-glucosidase enzyme derived from acremonium cellulolyticus, a polynucleotide encoding the β-glucosidase, an expression vector for expressing the β-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the β-glucosidase can be provided..
Honda Motor Co. Ltd.
01/15/15
20150017173

Antibodies to human transmembrane proteins


The invention provides human transmembrane proteins (htmpn) and polynucleotides which identify and encode htmpn. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation
01/15/15
20150017121

Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy


The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an il-12 polypeptide having a biological activity of il-12 or a nucleic acid expression vector comprising a sequence encoding such il-12 polypeptide, and a non-agonist ctla-4 ligand or non-agonist pd-1 ligand, particularly an anti-ctla-4 or anti-pd-1 immunoglobulin g..
Universitat Zurich
01/08/15
20150010518

Nr2e1 mini-promoters


Isolated polynucleotides comprising a nr2e1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
01/01/15
20150005473

Recombinant expression vector system for variants of coagulation factor viii and von willebrand factor


Disclosed is an expression vector system for variants of coagulation factor viii (fviii) and von willebrand factor (vwf). In detail, mutant vwf the size of which is significantly reduced by deleting exons but which has remarkably increased fviii stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with fviii are disclosed.
Korea University Industrial & Academic Collaborative Foundation
01/01/15
20150004165

Secreted proteins


The invention provides human secreted proteins (secp) and polynucleotides which identify and encode secp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation
01/01/15
20150004129

Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins


The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component a and at least one component b, whereby component a contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component b contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules.
Topotarget Switzerland Sa
12/25/14
20140378678

Compositions and methods for recombinant synthesis of high molecular weight hyaluronic acid


Provided is a novel hyaluronan synthase (has2), isolated nucleic acids encoding it, and expression vectors which express the novel has2. Also provided are cell cultures which contain cells which harbor the expression vectors, methods of using the cell cultures to produce high molecular weight hyaluronic acid, and cell culture media that contains the high molecular weight hyaluronic acid..
University Of Rochester
12/25/14
20140378389

T cell receptors recognizing hla-a1- or hla-cw7-restricted mage


The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for a) melanoma antigen family a (mage a)-3 in the context of hla-a1 or b) mage-a12 in the context of hla-cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
12/25/14
20140377869

Importation of mitochodrial protein by an enhanced allotopic approach


An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)
12/25/14
20140377801

Artificial signal peptide for expressing an insoluble protein as a soluble active form


The present invention relates to expression vectors and methods for enhancing soluble expression and secretion of an insoluble heterologous protein, particularly a bulky folded active heterologous protein which has one or more transmembrane-like domains or intramolecular disulfide bonds by linking a leader peptide with acidic or basic pl and high hydrophilicity thereto; by substituting one or more amino acids within n-terminal of the heterologous protein with ones having acidic or neutral pl and high hydrophilicity; or reducing elevating Δgrna value of a polynucleotide encoding the leader peptide having basic pl value and high hydrophilicity. The expression vector and the method may be used to produce of heterologous protein and to transduce of therapeutic proteins in a patient by preventing formation of insoluble inclusion body and by enhancing secretional efficiency of the heterologous protein into the periplasm or outside cell..
Republic Of Korea (republic Of National Fisheries Research And Development Institute)
12/18/14
20140373192

High efficiency plant expression promotor from capcicum annuum serine hydroxymethyl transferase gene and uses thereof


A high efficiency plant expression promoter from capsicum annuum serine hydroxymethyl transferase gene and uses thereof. This high efficiency plant expression promoter and 5′-untranslated region (5′-utr) from capsicum annular, serine hydroxymethyl transferase gene, a high efficiency plant expression vector having the same, a plant transformed with said vector, a process for high efficiency expression of a foreign gene by using said vector and a transformed plant which expresses with high efficiency a foreign gene based on said process and seeds of the transformed plant..
Industry Foundation Of Chonnam National University


Popular terms: [SEARCH]

Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         











0.5993

3819

1 - 1 - 72